Back to News
Market Impact: 0.2
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Source: Business Wire
Healthcare & Biotech
Seaport announced that the first patient has been dosed in its Phase 2a trial evaluating GlyphAgo in patients with generalized anxiety disorder and sleep disturbance. The headline reports a trial milestone but provides no efficacy, safety, enrollment, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
SPTX0.55
More News
- Seaport Therapeutics doses first patient in anxiety trial
- PureTech Health gets Panmure Liberum ‘buy' on value and cash returns
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results